

MAGE-A3 immunotherapeutic as adjuvant therapy for p  
MAGE-A3-positive, stage III melanoma (DERMA): a dou  
placebo-controlled, phase 3 trial

Lancet Oncology, The  
19, 916-929

DOI: [10.1016/s1470-2045\(18\)30254-7](https://doi.org/10.1016/s1470-2045(18)30254-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	CANCER VACCINES. Hematology/Oncology Clinics of North America, 2001, 15, 741-773.	0.9	25
2	Perspective: cancer vaccines in the era of immune checkpoint blockade. Mammalian Genome, 2018, 29, 703-713.	1.0	20
3	Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. Frontiers in Immunology, 2018, 9, 2531.	2.2	32
4	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer, 2018, 18, 1274.	1.1	31
6	A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clinical Cancer Research, 2018, 24, 6015-6027.	3.2	35
7	Negative but not futile: MAGE-A3 immunotherapeutic for melanoma. Lancet Oncology, The, 2018, 19, 852-853.	5.1	7
8	Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma. EBioMedicine, 2019, 46, 54-65.	2.7	31
9	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
10	Vaccine Strategy in Melanoma. Surgical Oncology Clinics of North America, 2019, 28, 337-351.	0.6	17
11	The Role of Toll-Like Receptors in Oncotherapy. Oncology Research, 2019, 27, 965-978.	0.6	23
12	Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology, 2019, 30, 1902-1913.	0.6	144
13	Cancer Vaccines. Hematology/Oncology Clinics of North America, 2019, 33, 199-214.	0.9	84
14	Immunomodulatory Nanosystems. Advanced Science, 2019, 6, 1900101.	5.6	255
15	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. American Journal of Clinical Dermatology, 2019, 20, 817-827.	3.3	29
16	Adaptive Signature Design- review of the biomarker guided adaptive phase III controlled design. Contemporary Clinical Trials Communications, 2019, 15, 100378.	0.5	10
17	Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. Clinical Cancer Research, 2019, 25, 6283-6294.	3.2	38
18	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers, 2019, 11, 677.	1.7	20
19	Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine, 2019, 37, 2915-2924.	1.7	20

#	ARTICLE	IF	CITATIONS
20	Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. <i>Phytomedicine</i> , 2019, 60, 152905.	2.3	108
21	Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	5
22	Gene Signatures in Cutaneous Malignancies. <i>Current Surgery Reports</i> , 2019, 7, 1.	0.4	4
23	Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application. <i>Cancer Letters</i> , 2020, 479, 54-60.	3.2	26
24	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. <i>Cancers</i> , 2020, 12, 1994.	1.7	26
25	Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. <i>Cancer Cell</i> , 2020, 38, 454-472.	7.7	190
26	Emerging roles of the MAGE protein family in stress response pathways. <i>Journal of Biological Chemistry</i> , 2020, 295, 16121-16155.	1.6	42
27	Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102032.	3.4	13
28	Promising targets based on pattern recognition receptors for cancer immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 105017.	3.1	27
29	Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-â€“Antigen Codelivery. <i>Vaccines</i> , 2020, 8, 128.	2.1	98
30	Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e200363.	2.8	49
31	The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 703-716.	2.0	28
32	Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells. <i>Clinical Sarcoma Research</i> , 2020, 10, 3.	2.3	11
33	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 663-675.	2.0	22
34	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , 2020, 52, 55-81.	6.6	357
35	An Open-Label Study of the Safety and Efficacy of <i>Tag-7</i> Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer. <i>Oncologist</i> , 2020, 25, e1303-e1317.	1.9	1
36	A Th1/IFN $\gamma$ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-â€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1725-1735.	3.2	13
37	Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 136-143.	1.5	9

#	ARTICLE	IF	CITATIONS
38	IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis. <i>Modern Pathology</i> , 2021, 34, 32-41.	2.9	29
39	Adjuvant Therapy of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 73-84.	0.9	2
40	MAGEA10 expression is a predictive marker of early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2021, 24, 341-351.	2.7	3
41	Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants. <i>Pharmaceutics</i> , 2021, 13, 140.	2.0	28
42	Cancer Vaccines: Antigen Selection Strategy. <i>Vaccines</i> , 2021, 9, 85.	2.1	30
43	Vaccine Therapies for Cancer: Then and Now. <i>Targeted Oncology</i> , 2021, 16, 121-152.	1.7	90
44	Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2151-2164.	2.0	6
45	Neoadjuvant and Adjuvant Therapies of Melanoma. , 2021, , 401-415.		0
46	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 615240.	2.2	59
47	Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3081-3091.	2.0	20
48	Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 623475.	1.6	6
49	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. <i>Vaccines</i> , 2021, 9, 454.	2.1	11
50	Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients. <i>Frontiers in Immunology</i> , 2021, 12, 659444.	2.2	17
51	AutoEncoder-Based Computational Framework for Tumor Microenvironment Decomposition and Biomarker Identification in Metastatic Melanoma. <i>Frontiers in Genetics</i> , 2021, 12, 665065.	1.1	0
52	Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions. <i>Vaccines</i> , 2021, 9, 535.	2.1	38
53	In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. <i>Advanced Materials</i> , 2021, 33, e2100628.	11.1	34
54	Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. <i>Vaccines</i> , 2021, 9, 668.	2.1	32
55	Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. <i>Molecular Pharmaceutics</i> , 2021, 18, 2867-2888.	2.3	65

#	ARTICLE	IF	CITATIONS
56	Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188558.	3.3	18
57	A novel era of cancer/testis antigen in cancer immunotherapy. <i>International Immunopharmacology</i> , 2021, 98, 107889.	1.7	36
58	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10
59	Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer. <i>Cancer Cell International</i> , 2021, 21, 473.	1.8	4
60	Emerging Therapies in the Treatment of Advanced Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 713-733.	0.7	3
61	Oncogenic activity and cellular functionality of melanoma associated antigen A3. <i>Biochemical Pharmacology</i> , 2021, 192, 114700.	2.0	10
62	The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739594.	1.8	4
63	The magic bullet as cancer therapeuticâ€”has nanotechnology failed to find its mark?. <i>Progress in Biomedical Engineering</i> , 2020, 2, 042004.	2.8	5
64	Vaccines for Non-Viral Cancer Prevention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10900.	1.8	4
65	Progress in adjuvant treatment of melanoma patients. <i>Nowotwory</i> , 2018, 68, 140-145.	0.1	0
66	Melanoma Vaccines. , 2019, , 1-23.		0
67	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-20.		0
68	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
70	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
71	Melanoma Vaccines. , 2020, , 1243-1265.		0
72	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
73	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
75	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0

#	ARTICLE	IF	CITATIONS
76	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	1.0	8
77	Functional nanomaterials and nanocomposite in cancer vaccines. , 2022, , 241-258.		0
78	When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies. <i>Frontiers in Oncology</i> , 2022, 12, 837995.	1.3	2
80	Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2412, 179-231.	0.4	7
81	Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 19.	0.9	28
82	Comprehensive Analysis to Identify MAGEA3 Expression Correlated With Immune Infiltrates and Lymph Node Metastasis in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 784925.	1.3	2
85	Volume doubling time and radiomic features predict tumor behavior of screen-detected lung cancers. <i>Cancer Biomarkers</i> , 2022, 33, 489-501.	0.8	4
86	Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies. <i>Communications Medicine</i> , 2022, 2, .	1.9	1
87	Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 730-737.	1.8	1
88	Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma. <i>Clinical Oncology</i> , 2023, 35, e85-e93.	0.6	1
89	Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. <i>British Journal of Cancer</i> , 2022, 127, 1584-1594.	2.9	21
90	Cancer vaccines: the next immunotherapy frontier. <i>Nature Cancer</i> , 2022, 3, 911-926.	5.7	207
91	Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113464.	2.5	4
92	Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. <i>Molecular Immunology</i> , 2022, 150, 58-66.	1.0	12
93	Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice. <i>International Immunopharmacology</i> , 2022, 111, 109093.	1.7	6
94	Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. <i>Translational Oncology</i> , 2022, 25, 101511.	1.7	2
95	Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells for immunotherapy of cancer. , 2022, 10, e004709.		7
96	Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
97	Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166557.	1.8	17
98	Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. <i>Advanced Science</i> , 2022, 9, .	5.6	20
99	Protein Informatics and Vaccine Development: Cancer Case Study. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2207-2220.	1.0	1
100	New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells. <i>Cancer Cell International</i> , 2022, 22, .	1.8	2
101	Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
102	Regulatory Landscapes in Approval of Cancer Vaccines. , 2022, , 325-347.		0
103	A Brief Overview of Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass )</i> , 2023, 29, 34-37.	1.0	0
104	Ex Vivo Model of Neuroblastoma Plasticity. <i>Cancers</i> , 2023, 15, 1274.	1.7	0
105	Cancer-testis non-coding RNA LEF1-AS1 regulates the nuclear translocation of PDCD5 and suppresses its interaction with p53 signaling: a novel target for immunotherapy in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 0, , .	1.3	0
106	Adjuvants approved for human use: What do we know and what do we need to know for designing good adjuvants?. <i>European Journal of Pharmacology</i> , 2023, 945, 175632.	1.7	4
107	The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?. <i>Cancers</i> , 2023, 15, 1779.	1.7	7
108	Clinical Trials for Personalized Medicine: Design and Data Analysis. <i>Japanese Journal of Biometrics</i> , 2022, 43, 97-119.	0.0	0
109	Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection. <i>Journal of Surgical Oncology</i> , 2023, 128, 97-104.	0.8	0
110	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103988.	2.0	2
115	Cancer Vaccines. , 2023, , 191-210.e9.		0
118	Circular RNA vaccine in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
119	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	1.5	0